Harrow Health (NASDAQ:HROW) – Analysts at B. Riley issued their Q3 2019 earnings estimates for shares of Harrow Health in a research note issued on Monday, November 11th. B. Riley analyst A. D’silva forecasts that the company will post earnings per share of ($0.02) for the quarter. B. Riley also issued estimates for Harrow Health’s FY2019 earnings at ($0.08) EPS.
Harrow Health (NASDAQ:HROW) last issued its earnings results on Wednesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.27). Harrow Health had a return on equity of 50.32% and a net margin of 51.32%. The firm had revenue of $12.76 million during the quarter, compared to analyst estimates of $13.31 million.
A number of other brokerages have also recently issued reports on HROW. ValuEngine raised Harrow Health from a “strong sell” rating to a “sell” rating in a report on Thursday. Lake Street Capital set a $15.00 target price on Harrow Health and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Zacks Investment Research cut Harrow Health from a “hold” rating to a “sell” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.83.
Shares of HROW opened at $5.68 on Wednesday. Harrow Health has a 12-month low of $4.10 and a 12-month high of $8.99. The business has a 50-day simple moving average of $5.23 and a two-hundred day simple moving average of $6.22. The company has a quick ratio of 3.60, a current ratio of 3.87 and a debt-to-equity ratio of 0.56. The stock has a market cap of $122.31 million, a PE ratio of 9.31 and a beta of 0.09.
In other Harrow Health news, Director Robert J. Kammer sold 6,500 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $4.75, for a total value of $30,875.00. Following the completion of the transaction, the director now owns 797,327 shares of the company’s stock, valued at approximately $3,787,303.25. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 19,500 shares of company stock valued at $101,855. Insiders own 12.43% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First National Bank of Omaha bought a new stake in shares of Harrow Health in the 3rd quarter valued at about $86,000. Vanguard Group Inc. grew its position in shares of Harrow Health by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,118,280 shares of the company’s stock valued at $9,729,000 after buying an additional 9,112 shares during the last quarter. BlackRock Inc. grew its position in shares of Harrow Health by 273.3% in the 2nd quarter. BlackRock Inc. now owns 430,524 shares of the company’s stock valued at $3,745,000 after buying an additional 315,209 shares during the last quarter. Cadence Capital Management LLC bought a new stake in shares of Harrow Health in the 2nd quarter valued at about $2,483,000. Finally, Renaissance Technologies LLC grew its position in shares of Harrow Health by 18.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,146,506 shares of the company’s stock valued at $9,975,000 after buying an additional 178,700 shares during the last quarter. Hedge funds and other institutional investors own 34.51% of the company’s stock.
Harrow Health Company Profile
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Featured Article: Quick Ratio
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.